GliaCure, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Madison WI United States (2011)

Organization Overview

First Clinical Trial
2014
NCT02254369
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Glia Cure | Glia, LLC | GLIA LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

progesterone (progestasert) (1 trial)

Drugs in Phase 2 Trials (2)

ganciclovir (cytovene) (2 trials)

gl101 (1 trial)

Drugs in Phase 1 Trials (1)

gc021109 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Glaucoma (Phase 2)

Graft vs Host Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4